세계의 고인산혈증 시장 : 지역별 분석 및 예측(2025-2035년)

Hyperphosphatemia Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035

US $ 4,900 ￦ 7,111,000

PDF and Excel (1-3 User License)

PDF 및 Excel 보고서를 동일 사업장에서 3명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 7,500 ￦ 10,885,000

PDF and Excel (Global License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계 고인산혈증 시장은 현재 라이프사이클의 성장기에 있으며, 수요 증가와 신장 질환 치료 옵션 증가가 그 특징입니다.

이러한 성장은 주로 만성콩팥병(CKD)의 유병률 증가, 특히 노년층에서 고인산혈증이 CKD 환자, 특히 투석 중인 환자들에게 중요한 질환으로 인식되고 있는 것에 기인하고 있습니다. CKD 환자 수가 증가하고 더 많은 치료제가 시장에 출시됨에 따라 각 업체들은 제품 포트폴리오를 강화하고 선진국과 신흥국 모두에서 시장 접근성을 강화하는 데 주력하고 있습니다. 하고 있습니다. 이러한 발전으로 시장은 성장세를 이어갈 것으로 예상되지만, 경쟁 심화, 제네릭 의약품 증가, 비용 억제 압력 등의 요인이 시장 성숙에 따른 과제로 부상할 수 있습니다.

영향력

• 고인산혈증 치료에 대한 수요 증가는 예측 기간 동안 세계 고인산혈증 시장의 성장을 가속할 것으로 예측됩니다.
• 진단 기술의 발전, 혁신적인 치료법 개발, 환자 및 의료진에 대한 인식 개선으로 세계 고인산혈증 시장은 향후 큰 성장이 기대되고 있습니다.

북미는 선진화된 의료 인프라, 높은 유병률, 질병에 대한 높은 인식으로 인해 예측 기간 동안 시장을 주도할 것으로 예측됩니다. 또한, 이 지역에는 강력한 제약 회사가 존재하여 효과적인 치료법을 조기에 제공할 수 있으며, 이는 세계 고인산혈증 시장의 성장을 더욱 촉진하고 있습니다.

세계의 고인산혈증(Hyperphosphatemia) 시장을 조사했으며, 주요 동향, 시장 영향요인 분석, 법 및 규제 환경, 임상시험 동향, 시장 규모 추이 및 예측, 각종 부문별/지역별/주요 국가별 상세 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

주요 요약

제1장 세계의 고인산혈증 시장 : 업계 전망

• 시장 개요와 에코시스템
• 시장 동향
• 고인산혈증 역학적 분석
• 임상시험
  • 단계별
  • 스폰서 유형별
• 규제 상황/컴플라이언스
  • 미국의 법적 요건과 프레임워크
  • EU의 법적 요건과 프레임워크
  • 아시아태평양의 법적 요건과 프레임워크
• 시장 역학
  • 영향 분석
  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회

제2장 세계의 고인산혈증 시장 : 지역별

• 북미
• 유럽
• 아시아태평양
  • 시장 역학
  • 시장 규모와 예측

제3장 세계의 고인산혈증 시장 : 경쟁 벤치마킹 및 기업 개요

• 경쟁 구도
  • 기업의 주요 전략과 전개
  • 주요 전개 분석
• 기업 개요
  • Kyowa Kirin, Inc.
  • Bayer
  • Unicycive Therapeutics
  • Sanofi
  • Shanghai Alebund Pharmaceuticals Limited
  • Ardelyx
  • Kissei Pharmaceutical Co. Ltd.
  • Astellas Pharma Inc.
  • Mitsubishi Tanabe Pharma Corporation

제4장 조사 방법

LSH

영문 목차

영문목차

Market Lifecycle Stage

The global hyperphosphatemia market is currently in the growth stage of its lifecycle, marked by expanding demand and increasing renal treatment options. This growth is primarily driven by the rising prevalence of chronic kidney disease (CKD), particularly among aging populations, and the growing recognition of hyperphosphatemia as a critical condition in CKD patients, especially those on dialysis. Additionally, regulatory bodies such as the FDA are fast-tracking approvals for new treatments, which is fueling further market expansion. As the number of patients with CKD increases and more treatments enter the market, companies are focusing on enhancing their product portfolios and strengthening market access, both in developed and emerging markets. With these advancements, the market is expected to maintain its growth trajectory, although increased competition, rising generic alternatives, and cost containment pressures may pose challenges as the market matures.

Impact

• Increasing demand for hyperphosphatemia therapies is anticipated to support the growth of the global hyperphosphatemia market during the forecast period 2025-2035.
• The global hyperphosphatemia market is expected to grow at a significant rate due to advancements in diagnostic technologies, the development of innovative therapies, and increasing awareness among patients and healthcare providers.

North America is expected to dominate the global hyperphosphatemia market during the forecast period due to its advanced healthcare infrastructure, high prevalence, and increased awareness of the disease. The region also benefits from a strong pharmaceutical presence, which accelerates the availability of effective treatments and drives the growth of the global hyperphosphatemia market.

Recent Developments

• Regulatory Activities: In September 2024, Unicycive Therapeutics announced the submission of an NDA to the U.S. FDA for Oxylanthanum Carbonate, intended for the treatment of hyperphosphatemia in patients with chronic kidney disease undergoing dialysis.
• Regulatory Activities: In July 2024, the U.S. FDA expanded the approval of Velphoro (sucroferric oxyhydroxide) for use in patients as young as 9 years old. The drug, previously approved only for adults, is used to control serum phosphorus levels in patients with chronic kidney disease (CKD) undergoing dialysis.

Demand - Drivers and Limitations

Drivers:

• Rising Prevalence of Chronic Kidney Disease
• Continuous Advancements in Treatment Options

Challenges:

• Economic Barriers in Emerging Markets

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: Product launches and innovations in the global hyperphosphatemia market are focused on advancing treatment options to improve patient care. These innovations aim to enhance the efficacy of therapies and streamline the detection and management of the disease. Key players in the market, such as Unicycive Therapeutics, have been involved in the development of therapies for hyperphosphatemia.

Competitive Strategy: Enterprises led by market leaders in the global hyperphosphatemia market are continuously working on updating their product portfolios with innovative treatments to maintain competitiveness. A detailed competitive benchmarking of the key players has been conducted, providing insights into how these companies compare in terms of product offerings, market share, and innovation. This benchmarking provides readers with a clear understanding of the market landscape and the positions of the leading players. Additionally, comprehensive competitive strategies, such as partnerships, agreements, and collaborations, will help readers identify untapped revenue opportunities in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and by analyzing company coverage, product portfolio, and market penetration.

Some of the prominent names established in this market are:

• Kyowa Kirin, Inc.
• Bayer
• Unicycive Therapeutics
• Sanofi
• Shanghai Alebund Pharmaceuticals Limited
• Ardelyx
• Kissei Pharmaceutical Co. Ltd.
• Astellas Pharma Inc.
• Mitsubishi Tanabe Pharma Corporation

Table of Contents

Executive Summary

Scope of Study

1. Global Hyperphosphatemia Market: Industry Outlook

• 1.1 Market Overview and Ecosystem
• 1.2 Market Trends
• 1.3 Epidemiological Analysis of Hyperphosphatemia
  • 1.3.1 By Region
• 1.4 Clinical Trials
  • 1.4.1 By Phase
  • 1.4.2 By Sponsor Type
• 1.5 Regulatory Landscape / Compliance
  • 1.5.1 Legal Requirement and Framework in the U.S.
  • 1.5.2 Legal Requirement and Framework in the E.U.
  • 1.5.3 Legal Requirement and Framework in Asia-Pacific
• 1.6 Market Dynamics
  • 1.6.1 Impact Analysis
  • 1.6.2 Market Drivers
  • 1.6.3 Market Restraints
  • 1.6.4 Market Opportunities

2. Global Hyperphosphatemia Market, By Region, $Million, 2023-2035

• 2.1 North America
  • 2.1.1 Market Dynamics
  • 2.1.2 Market Sizing and Forecast
    • 2.1.2.1 North America Hyperphosphatemia Market (by Country)
      • 2.1.2.1.1 U.S.
• 2.2 Europe
  • 2.2.1 Market Dynamics
  • 2.2.2 Market Sizing and Forecast
    • 2.2.2.1 Europe Hyperphosphatemia Market (by Country)
      • 2.2.2.1.1 U.K.
      • 2.2.2.1.2 Germany
      • 2.2.2.1.3 France
      • 2.2.2.1.4 Italy
• 2.3 Asia-Pacific
  • 2.3.1 Market Dynamics
  • 2.3.2 Market Sizing and Forecast
    • 2.3.2.1 Asia-Pacific Hyperphosphatemia Market (by Country)
      • 2.3.2.1.1 Japan

3. Global Hyperphosphatemia Market - Competitive Benchmarking and Company Profiles

• 3.1 Competitive Landscape
  • 3.1.1 Key Strategies and Developments by Company
    • 3.1.1.1 Funding Activities
    • 3.1.1.2 Mergers and Acquisitions
    • 3.1.1.3 Regulatory Approvals
    • 3.1.1.4 Partnerships, Collaborations and Business Expansions
  • 3.1.2 Key Developments Analysis
• 3.2 Company Profiles
  • 3.2.1 Kyowa Kirin, Inc.
    • 3.2.1.1 Company Overview
    • 3.2.1.2 Product Portfolio
    • 3.2.1.3 Target Customers/End Users
    • 3.2.1.4 Analyst View
  • 3.2.2 Bayer
    • 3.2.2.1 Company Overview
    • 3.2.2.2 Product Portfolio
    • 3.2.2.3 Target Customers/End Users
    • 3.2.2.4 Analyst View
  • 3.2.3 Unicycive Therapeutics
    • 3.2.3.1 Company Overview
    • 3.2.3.2 Product Portfolio
    • 3.2.3.3 Target Customers/End Users
    • 3.2.3.4 Analyst View
  • 3.2.4 Sanofi
    • 3.2.4.1 Company Overview
    • 3.2.4.2 Product Portfolio
    • 3.2.4.3 Target Customers/End Users
    • 3.2.4.4 Analyst View
  • 3.2.5 Shanghai Alebund Pharmaceuticals Limited
    • 3.2.5.1 Company Overview
    • 3.2.5.2 Product Portfolio
    • 3.2.5.3 Target Customers/End Users
    • 3.2.5.4 Analyst View
  • 3.2.6 Ardelyx
    • 3.2.6.1 Company Overview
    • 3.2.6.2 Product Portfolio
    • 3.2.6.3 Target Customers/End Users
    • 3.2.6.4 Analyst View
  • 3.2.7 Kissei Pharmaceutical Co. Ltd.
    • 3.2.7.1 Company Overview
    • 3.2.7.2 Product Portfolio
    • 3.2.7.3 Target Customers/End Users
    • 3.2.7.4 Analyst View
  • 3.2.8 Astellas Pharma Inc.
    • 3.2.8.1 Company Overview
    • 3.2.8.2 Product Portfolio
    • 3.2.8.3 Target Customers/End Users
    • 3.2.8.4 Analyst View
  • 3.2.9 Mitsubishi Tanabe Pharma Corporation
    • 3.2.9.1 Company Overview
    • 3.2.9.2 Product Portfolio
    • 3.2.9.3 Target Customers/End Users
    • 3.2.9.4 Analyst View

4. Research Methodology

관련자료